Genetic Testing

The Era of DTC Diagnostics, Diagnosis and Drug Development Is Here

The Era of DTC Diagnostics, Diagnosis and Drug Development Is Here

Despite conventional wisdom that the 23andMe business breakthrough is the direct-to-consumer model, it's also the consolidation of genetic testing, diagnosis and drug development that has the potential to change the industry.

Five things for pharma marketers to know: Wednesday, October 21, 2015

Five things for pharma marketers to know: Wednesday, October 21, 2015

By

23andMe relaunches its DTC genetic test; Valeant's woes increase as shares plummet; the FDA questions the safety of AstraZeneca's gout drug

Five things for pharma marketers to know: Thursday, July 9

Five things for pharma marketers to know: Thursday, July 9

By

Pregnant women taking Prozac or Paxil have higher risks of birth defects; study finds J&J's experimental psoriasis drug works better than Humira; AstraZeneca divests global rights to Entocort

Clinton tells pharma to explain drug prices

Clinton tells pharma to explain drug prices

Speakers at Klick Health's event criticized, lauded the role of technology in healthcare.

Five things for pharma marketers to know: Friday, May 15

Five things for pharma marketers to know: Friday, May 15

By

Genentech alums launch a new biotechnology company; Mallinckrodt sues the FDA over a drug reclassification; Sanofi takes on celiac disease

Myriad expands companion diagnostic deals

Myriad expands companion diagnostic deals

By

The company partnered with AstraZeneca and BioMarin to identify which patients respond to experimental cancer drugs.

Five things for pharma marketers to know: Tuesday, April 21

Five things for pharma marketers to know: Tuesday, April 21

By

Teva proposes acquisition of Mylan; start-up offers BRCA testing for $249; Botox receives another label expansion

OPINION

Email Newsletters